| Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS–NSTEMI … J Layland, KG Oldroyd, N Curzen, A Sood, K Balachandran, R Das, ... European heart journal 36 (2), 100-111, 2015 | 341* | 2015 |
| Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial K Willett, DJ Keene, D Mistry, J Nam, E Tutton, R Handley, L Morgan, ... Jama 316 (14), 1455-1463, 2016 | 136* | 2016 |
| The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open … DJ Keene, D Mistry, J Nam, E Tutton, R Handley, L Morgan, E Roberts, ... Health Technology Assessment (Winchester, England) 20 (75), 1, 2016 | 108 | 2016 |
| Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patients J Nam, K Caners, JM Bowen, M Welsford, D O'Reilly Annals of emergency medicine 64 (2), 176-186. e9, 2014 | 95 | 2014 |
| A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT) A Gumley, R White, A Briggs, I Ford, S Barry, C Stewart, S Beedie, ... Schizophrenia Research 183, 143-150, 2017 | 52 | 2017 |
| Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis J Nam, H Jing, D O'Reilly International Journal of Stroke 10 (1), 13-22, 2015 | 49 | 2015 |
| Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact KM Johnston, BS Sheffield, S Yip, P Lakzadeh, C Qian, J Nam Current Oncology 27 (6), e569, 2020 | 29 | 2020 |
| Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC) U Ondhia, HJ Conter, S Owen, A Zhou, J Nam, S Singh, A Abdulla, P Chu, ... Journal of medical economics 22 (7), 625-637, 2019 | 28 | 2019 |
| Bayesian solutions for handling uncertainty in survival extrapolation MA Negrín, J Nam, AH Briggs Medical Decision Making 37 (4), 367-376, 2017 | 24 | 2017 |
| Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental … J Nam, A Briggs, J Layland, KG Oldroyd, N Curzen, A Sood, ... Cost Effectiveness and Resource Allocation 13, 1-9, 2015 | 18 | 2015 |
| Evaluation of health in pregnancy grants in Scotland: a natural experiment using routine data AH Leyland, S Ouédraogo, J Nam, L Bond, AH Briggs, R Gray, R Wood, ... Public Health Research 5 (6), 2017 | 17 | 2017 |
| Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC) KM Johnston, BS Sheffield, S Yip, P Lakzadeh, C Qian, J Nam Journal of Medical Economics 23 (10), 1123-1129, 2020 | 16 | 2020 |
| Health and budget impact of liquid-biopsy-based comprehensive genomic profile (CGP) testing in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients YP Patel, D Husereau, NB Leighl, B Melosky, J Nam Current Oncology 28 (6), 5278-5294, 2021 | 15 | 2021 |
| Reverse engineering of digital measures: inviting patients to the conversation I Clay, N Peerenboom, DE Connors, S Bourke, A Keogh, K Wac, ... Digital Biomarkers 7 (1), 28-44, 2023 | 11 | 2023 |
| Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia J Nam, R Milenkovski, S Yunger, M Geirnaert, K Paulson, M Seftel Journal of Medical Economics 21 (1), 47-59, 2018 | 9 | 2018 |
| PPM11 tumour-specific randomized controlled trials in rare oncogene-driven cancers: asking for the impossible? G Lozano-Ortega, M Hodgson, F Csintalan, C Zerbini, K Johnston, J Nam Value in Health 22, S838-S839, 2019 | 7 | 2019 |
| Fractional flow reserve versus Coronary Angiography guided management in non-st elevation myocardial infarction: a Health economic analysis J Nam, A Briggs, J Layland, K Oldroyd, N Curzen, A Sood, ... Value in Health 18 (3), A46, 2015 | 2 | 2015 |
| PPM5 costs of in-house mutational-testing and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC) J Nam, P Lakzadeh, K Johnston, S Yip, C Qian, B Sheffield Value in Health 22, S837-S838, 2019 | 1 | 2019 |
| PPM4 Comprehensive genomic profiling for non-small cell lung cancer (NSCLC): a health and budget impact analysis J Nam, K Johnston, S Yip, C Qian, P Lakzadeh, B Sheffield Value in Health 22, S837, 2019 | 1 | 2019 |
| OP86 Evaluating Health in Pregnancy grants in Scotland: a natural experiment AH Leyland, S Ouédraogo, R Gray, L Bond, AH Briggs, J Nam, R Wood, ... J Epidemiol Community Health 70 (Suppl 1), A47-A48, 2016 | 1 | 2016 |
Daria O'Reilly, PhDAssociate Professor of Health Technology Assessment, McMaster UniversityZweryfikowany adres z mcmaster.ca